IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IBI-343’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IBI-343 is under development for the treatment of metastatic solid tumors including adenocarcinoma of the gastroesophageal junction, pancreatic ductal adenocarcinoma, biliary tract cancer, gastric cancer and unspecified cancer. The drug candidate is a monoclonal antibody conjugate that acts by targeting cells expressing claudin 18.2. It is administered intravenously.
Innovent Biologics overview
Innovent Biologics is a biopharmaceutical company that focuses on the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112, IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311
For a complete picture of IBI-343’s drug-specific PTSR and LoA scores, buy the report here.